These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 3011046)

  • 1. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Hockings N; Ajayi AA; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):341-8. PubMed ID: 3011046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment.
    Lees KR; Reid JL
    Clin Pharmacol Ther; 1987 Jun; 41(6):597-602. PubMed ID: 3034468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.
    Weisser K; Schloos J; Jakob S; Mühlberg W; Platt D; Mutschler E
    Eur J Clin Pharmacol; 1992; 43(2):173-7. PubMed ID: 1330574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of renal function on enalapril kinetics.
    Lowenthal DT; Irvin JD; Merrill D; Saris S; Ulm E; Goldstein S; Hichens M; Klein L; Till A; Harris K
    Clin Pharmacol Ther; 1985 Dec; 38(6):661-6. PubMed ID: 2998676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
    Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
    J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
    Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
    Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic and metabolic aspects of enalapril action.
    Lant AF; McNabb RW; Noormohamed FH
    J Hypertens Suppl; 1984 Dec; 2(2):S37-42. PubMed ID: 6100875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
    Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
    Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis.
    Matalka K; Arafat T; Hamad M; Jehanli A
    Fundam Clin Pharmacol; 2002 Jun; 16(3):237-44. PubMed ID: 12165071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.
    Elung-Jensen T; Heisterberg J; Sonne J; Strandgaard S; Kamper AL
    Eur J Clin Pharmacol; 2005 Apr; 61(2):87-96. PubMed ID: 15761754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril.
    Ajayi AA; Campbell BC; Kelman AW; Howie C; Meredith PA; Reid JL
    Int J Clin Pharmacol Res; 1985; 5(6):419-27. PubMed ID: 3005181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
    Reams GP; Lal SM; Whalen JJ; Bauer JH
    J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of angiotensin converting enzyme (ACE) in the pharmacokinetics and pharmacodynamics of ACE inhibitors.
    Johnston CI; Jackson B; Cubela R; Larmour I; Arnolda L
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S9-14. PubMed ID: 2422495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
    Edeki T; Johnston A; Li Kam Wa E; Turner P
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
    Worland PJ; Jarrott B
    J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W; Muscará MN; Martins AR; Moreno H; Mendes GB; de Nucci G
    Eur J Clin Pharmacol; 1996; 50(5):399-405. PubMed ID: 8839663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.